Introduction {#S1}
============

Alzheimer's disease (AD) is the most common cause of dementia. Estimates have revealed that in 2050, the number of people with AD aged 65 years and older will be triple ([@B1]). Presently, no curative treatment is available for AD. The most effective symptomatic pharmacological treatment for AD is cholinesterase inhibitors (ChEIs), which delay the progress of cognitive dysfunction ([@B2]). However, the response to ChEI treatment is variable. Higher cognitive profile, a previous intellectual occupation, healthier lifestyles, being married and not living alone, a higher degree of autonomy, and lower degree of brain atrophy at baseline were associated with better response to ChEI ([@B3]). The genotype of apolipoprotein E (ApoE), a cholesterol-transporting enzyme is strongly associated with AD. However, whether ApoE genotype affects the response to ChEI in people with AD is controversial. It had been demonstrated that ApoE ε4 allele carriers were poor responders to tacrine ([@B4]); nevertheless, other studies revealed that this detrimental genotype carriers exhibited better response to donepezil ([@B5], [@B6]). Evidence from several prospective, randomized, placebo-controlled trials with large samples were consistent with that ApoE was not a good predictor of response to ChEIs ([@B7]--[@B10]).

Vitamin B12 has been identified to be associated with cognitive function. Vitamin B12 deficiency because of a vegetarian diet, gastric surgery, malnutrition, or alcoholism results in cognitive dysfunction, and vitamin B12 supplementation can be applied as a rescue treatment for "reversible dementia" ([@B11]). A low vitamin B12 level is associated with increasing risks of AD and behavioral and psychological symptoms of dementia in people with AD ([@B12], [@B13]). Although a previous study reported that vitamin B12 supplementation failed to demonstrate neuroprotection in AD ([@B14]), the significance of vitamin B12 in AD should not be underestimated.

According to the Taiwan National Health Insurance (NHI) guideline, the insurance-coverage of ChEI treatment is only available to people with AD after vitamin B12 deficiency has been ruled out. Therefore, baseline serum vitamin B12 level measurements were available for all people with approval for the ChEI prescription. The present study investigated whether the baseline vitamin B12 level was associated with the deterioration of cognitive function in Taiwanese people with AD undergoing ChEI treatment.

Materials and Methods {#S2}
=====================

Patient Selection {#S2-1}
-----------------

This retrospective study was approved by the Joint Institutional Review Board of Taipei Medical University (TMU-JIRB) (Approval No. N201707049) and waived of informed consent was agreed by TMU-JIRB due to (1) the risk of participants is minimal and (2) waiving of informed consent is no harmful for the right of participants. Medical records from Shuang Ho Hospital between August 2009 and December 2016 were reviewed. During this period, there were 165 people with mild to moderate AD \[baseline Mini--Mental State Examination (MMSE) between 10 and 26\] who (1) underwent NHI-approved ChEI treatment (2) regular follow-up through cognitive function tests for at least two years. To avail of the insurance-coverage of ChEI treatment, the Taiwan NHI requires that patients should fulfill the following criteria: 1. AD diagnosis (DSM-IV diagnostic criteria of AD) and without any comorbidity affecting cognitive function, such as obvious vascular insults, vitamin B12 (≥206 ng/L), or folate deficiency, or metabolic disorder; 2. a review process to assess all medical records of the patient. The review is conducted by an NHI committee consisting of either neurologists or psychiatrists. After receiving NHI approval for ChEI treatment, patients are required to receive at least annual follow-up through the MMSE, and ChEI treatment would be discontinued for patients with MMSE decline of more than 2 points year-by-year.

The present study collected baseline medical and personal records, including age; sex; education years; medical history of hypertension, diabetes, and cerebrovascular accident (CVA); and serum vitamin B12 and folate. Since vitamin B12 level is known to be affected by several drugs (colchicine, proton pump inhibitors, histamine H2-receptor antagonists, metformin, and antiepileptic agents) and medical conditions (alcohol consumption, peptic ulcer, or gastric operation), specific drug and medical history were also recorded. All patients received MMSE and Cognitive Abilities Screening Instrument (CASI) tests at least three times: at the baseline, first follow-up, and second follow-up, with a 1-year interval. The longest follow-up period was 8 years. For ChEI treatment, donepezil (5 and 10 mg) and rivastigmine (1.5 and 4.5-mg pill and 10-mg patch) were available in Shuang Ho Hospital. People with AD were allowed to switch medications if side effects were intolerable. The deterioration of MMSE and CASI was determined by calculating the ratio of the difference in scores between the baseline and last cognitive tests (unit: score) to the time interval between two tests (unit: year).

Statistical Analyses {#S2-2}
--------------------

All statistical analyses were performed using SPSS for Windows 10 (version 19; SPSS Inc., Chicago, IL, USA). Continuous variables are presented as mean ± SD, and categorical variables are presented as percentages with corresponding 95% confidence intervals. The differences were analyzed using Student's *t* test. The multivariate logistic regression model was adjusted for the following variables: age; sex; education level; initial cognitive function test (either the MMSE or CASI); history of hypertension, diabetes, and CVA; and baseline folate level. A *p*-value of \<0.05 was considered statistically significant.

Results {#S3}
=======

All 165 people with AD underwent ChEI treatment for at least 2 years and were followed through annual cognitive examination (the MMSE and CASI). Their median age was 76 years (ranging from 54 to 91) while initiating treatment; 112 of them were women; and their median education years was 6 years (ranging from 0 to 16). The median level of vitamin B12 was 436 ng/L (ranging from 206 to 5,454). The distribution of serum vitamin B12 was a two-tailed normal distribution pattern (Figure S1 in Supplementary Material).

Furthermore, people with AD were categorized into two groups based on their baseline vitamin B12 levels: the group with optimal baseline vitamin B12 level (above median, 436 ng/L, *n* = 82) and suboptimal baseline vitamin B12 level (*n* = 83) (Table [1](#T1){ref-type="table"}). Comparison between these two groups revealed no significant difference in most of the background demographic characteristics, including age, education years, major medical history, and baseline MMSE and CASI scores. However, more women (65 versus 47, *p* = 0.003) were in the optimal vitamin B12 group. Moreover, patients in the optimal B12 group had a significantly higher folate level. In both groups, donepezil was the main choice of ChEI treatment and the dosage of donepezil among the majority of them were titrated up to 10 mg daily. Only few of participants in both groups were exposure to drugs which may affect vitamin B12, mainly metformin.

###### 

Demographic data of all patients categorized into optimal vitamin B12 (\>436 ng/L) and suboptimal (≤436 ng/L) groups.

  --------------------------------------------------------------------------------------------------------------------
                                      Optimal vitamin B12 (*n* = 82)   Suboptimal vitamin B12 (*n* = 83)   *p*-Value
  ----------------------------------- -------------------------------- ----------------------------------- -----------
  Women (%)                           65 (79.3)                        47 (56.6)                           0.003

  Age (years)                         76.01 ± 6.93                     75.41 ± 8.46                        0.618

  Education (years)                   5.46 ± 4.81                      7.10 ± 4.23                         0.019

  Hypertension (%)                    30 (36.6)                        38 (45.8)                           0.269

  Diabetes (%)                        17 (20.7)                        25 (30.1)                           0.211

  CVA (%)                             9 (11.0)                         9 (10.8)                            1.000

  Folate (ng/mL)                      15.79 ± 10.52                    11.14 ± 10.46                       0.005

  Baseline MMSE                       18.33 ± 5.00                     19.28 ± 4.38                        0.197

  Baseline CASI                       60.30 ± 16.57                    64.83 ± 13.67                       0.057

  ChEIs                               Donepezil 5 mg, *n* = 12\        Donepezil 5 mg, *n* = 21\           0.253
                                      Donepezil 10 mg, *n* = 50\       Donepezil 10 mg, *n* = 43\          
                                      Rivastigmine, *n* = 20           Rivastigmine, *n* = 19              

  Medications affecting Vitamin B12   Metformin, *n* = 7\              Metformin, *n* = 11\                
                                      PPI, *n* = 4\                    AED, *n* = 3\                       
                                      AED, *n* = 1\                    Colchicine, *n* = 1                 
                                      H2 blockers, *n* = 1                                                 

  MMSE decline/year                   0.78 ± 1.28                      1.42 ± 1.67                         0.007

  CASI decline/year                   2.84 ± 4.21                      4.95 ± 5.88                         0.009
  --------------------------------------------------------------------------------------------------------------------

*CVA, cerebrovascular accident; MMSE, Mini--Mental State Examination; CASI, Cognitive Abilities Screening Instrument; ChEI, cholinesterase inhibitor; PPI, proton pump inhibitor; AED, antiepileptic drug; H2, histamine H2 receptors*.

The present study aimed to investigate the effect of baseline vitamin B12 on the response to ChEI treatment for cognitive decline in people with AD. After the first 2-year treatment, participants in both groups demonstrated a decline in the MMSE and CASI with highly variable results of cognitive function test within the group (Figure [1](#F1){ref-type="fig"}). However, if extending the follow-up period to the end of ChEI treatment (maximum follow-up period: 8 years), for patients with optimal vitamin B12 level, the corresponding cognitive decline was significantly slower than suboptimal vitamin B12 group of patients (MMSE decline: 0.78 ± 1.28 versus 1.42 ± 1.67 point/year, *p* = 0.007; CASI decline: 2.84 ± 4.21 versus 4.95 ± 5.88 point/year, *p* = 0.009) (Table [1](#T1){ref-type="table"}).

![The box plots demonstrated the results of Mini--Mental State Examination (MMSE) and Cognitive Abilities Screening Instrument (CASI) at baseline and 2-year follow-up for patients with optimal (\>436 ng/L) or suboptimal baseline vitamin B12 level.](fneur-09-00325-g001){#F1}

If further categorized all the patients into four groups by first, second, and third quartile, the results demonstrated a similar pattern that people with higher baseline vitamin B12 level demonstrated less cognitive decline (Table S1 in Supplementary Material).

Because several factors affect cognitive decline, including age, education years, comorbidities, and baseline cognitive function before treatment, we applied a multivariable regression model to investigate the association between the baseline serum vitamin B12 level and cognitive decline. After adjustment for the aforementioned factors, the baseline vitamin B12 level was significantly and negatively associated with cognitive decline (MMSE decline, *p* = 0.009; CASI decline, *p* = 0.014) (Table [2](#T2){ref-type="table"}).

###### 

Multivariable regression model of the association between high vitamin B12 level and deterioration of cognitive function.

                Deterioration of Mini--Mental State Examination (MMSE)   Deterioration of Cognitive Abilities Screening Instrument (CASI)            
  ------------- -------------------------------------------------------- ------------------------------------------------------------------ -------- -------
  Vitamin B12   −0.214                                                   0.009                                                              −0.195   0.014

*The model was adjusted for age; sex; education level; initial cognitive function test (either MMSE or CASI); history of diabetes, and CVA; and baseline folate level*.

Discussion {#S4}
==========

The present study showed that the baseline vitamin B12 level was negatively associated with cognitive decline in people with AD undergoing ChEI treatment. The deterioration of cognitive function, as assessed by the MMSE and CASI, was significantly slower in patients with optimal baseline vitamin B12 level. Moreover, after adjustment of age, sex, education level, comorbidity, and baseline cognitive function, the baseline vitamin B12 level was negatively associated with cognitive decline. The results demonstrate that the suboptimal baseline vitamin B12 level was associated with poorer response to ChEI treatment in people with AD.

Vitamin B12 deficiency is associated with damage to the white matter in the spinal cord and in the brain, which adversely affects neuronal function. The exact mechanism underlying this association remains unknown. Damage to myelin as a result of defective methylation of myelin basic protein (MBP) has been postulated as an underlying mechanism. MBP accounts for approximately one-third of myelin protein, and demyelination in the setting of vitamin B12 deficiency may explain many of the neurologic findings, including the association with cognitive decline ([@B15], [@B16]). Another hypothesis is the alteration of the concentrations of cytokines, such as tumor necrosis factor-α or epidermal growth factor ([@B17]). A low vitamin B12 status leads to *S*-adenosylmethionine deficiency, which results in defective methylation reactions in the central nervous system ([@B18]). In a longitudinal study, the serum holotranscobalamin level was found to be related to cognitive performance 7 years later, even in elderly subjects without dementia, and a higher holotranscobalamin level tended to be related to higher performance in executive functions and psychomotor speed ([@B19]). Another study conducted in participants aged 45--69 years showed that participants whose vitamin B12 level was in the highest quartile had significantly higher verbal fluency scores ([@B20]). The Framingham Heart Study that included community-dwelling individuals aged 74.8 ± 4.6 years showed that plasma vitamin B12 levels ranging from 187 to 256.8 pmol/L predicted cognitive decline ([@B21]). Cohort studies have also demonstrated the association of low vitamin B12 status with cognitive dysfunction and cognitive decline ([@B22], [@B23]). A longitudinal cohort study that included 97 people with AD also revealed that baseline homocysteine levels showed a concentration--response relationship with the subsequent rate of decline in cognitive tests ([@B24]). However, in clinical practice, it was found that people with cognitive impairment, which is associated with vitamin B12 deficiency, did not always improve on treatment, whereas those with obvious dementia usually showed no improvement ([@B25]). Connelly suggested that the isolated use of B vitamins and folic acid is ineffective in improving cognition in people with AD, although homocysteine levels were normal or mildly increased ([@B26]). In a systematic review of four randomized controlled trials, vitamin B supplementation was found to be effective in reducing serum homocysteine levels but not in facilitating cognitive improvement ([@B27]). In a meta-analysis of 11 randomized trials involving 22,000 participants, Clarke et al. argued that 5-year dietary supplementation with B vitamins did not have any effect on cognitive domains, global cognitive function, or cognitive aging in older people ([@B28]).

The present study has some limitations. Although the medical chart review could identify numerous useful information, it was shortage of certain valuable factors for research. For instance, the present study failed to provide the ApoE genetic information, which is the strongest genetic determinant of AD. However, as aforementioned, whether ApoE genotype affects the response of ChEI was controversial. In addition, activities of daily living and instrumental activities of daily living assessments were not routinely performed in the clinical setting, so authors were not able to provide this information. On the other hand, according to the NHI guidelines about the insurance-coverage ChEI treatment, all people with AD with approved ChEI treatment are required to receive the cognitive function test annually. However, this treatment may be discontinued in patients with cognitive decline of more than 2 points in MMSE year-by-year; thus, the follow-up of cognitive function may stop. Our patients received ChEI treatment for at least 2 years, indicating that they were not the early non-responders to ChEI treatment in the first 12 months. Patients with a longer follow-up duration had a more benign course of AD. Therefore, this population was not exactly real-world people with AD but a group of partial or good responders to ChEI treatment. In addition, the vitamin B12 level of the study patients was not followed up annually. Without follow-up, no information was available to determine the correlation between the change in vitamin B12 and cognitive function and the effect of vitamin B12 supplementation on cognitive decline.

In conclusion, the present study demonstrated that suboptimal baseline serum vitamin B12 level was associated with rapid cognitive decline in people with AD undergoing ChEI treatment. Additional studies are required to delineate whether the alteration of the vitamin B12 level during the ChEI treatment period is correlated with cognitive change and to identify the specific people with AD who may be the responders to vitamin B12 supplementation.
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